Geneseeq

← Hematologic Malignancy-Specific Gene Panels

BRCAscan™ analyzes 26 key genes associated with homologous recombination repair (HRR) pathways, including BRCA1/BRCA2, and ERBB2 to inform treatment decisions such as PARP inhibitors selection and assess genetic predisposition to breast, ovary, prostate and pancreatic cancers.

Geneseeq provides a dedicated Breast Cancer HRD Panel for assessing homologous recombination deficiency. Identify HRD status to guide PARP inhibitor treatment decisions and personalize therapy for breast cancer patients.

Geneseeq’s PanTRKare™ NGS companion diagnostic for NTRK1/2/3 gene fusions gains a third NMPA-approved CDx application for VELMARTO® (eratrectinib).

TORONTO, August 31 – Currently, there is no reliable clinical indicator to accurately assess the treatment response of neoadjuvant chemoradiotherapy […]

Early risk stratification and assessment of adjuvant chemotherapy (ACT) efficacy for localized colorectal cancer (CRC) are still lacking in a […]

One of the easiest ways to improve travel photos is shooting in better light, and the best light is often in the hour after sunrise and before sunset. That’s because the light takes on a warm golden hue and hits the subject from the side instead of the top. t’s difficult to recreate the grandeur of a vast landscape in the confines of a picture frame.

Researchers published promising clinical data in the Journal for ImmunoTherapy of Cancer (JITC), from two phases I clinical trials using […]

TORONTO, January 25, 2021,10:00 ET – Geneseeq Technology Inc. (“Geneseeq”), along with our clinical collaborators will be presenting new data at the […]

Geneseeq Technology Inc., along with our clinical collaborators will present new data at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, which will held from May 29 to May 31. Twenty of our studies have been selected by the ASCO committee, including one oral presentation and eight poster presentations covering topics on advances in genomic profiling technology, novel biomarker and cancer genomic discoveries. Geneseeq will also participate in the virtual exhibit

Geneseeq, industry leader in next-generation sequencing (NGS) will collaborate with Illumina, global leader in DNA sequencing and array-based technologies,to develop an oncogene detection kit for clinical diagnosis based on its industry-leading sequencing techology. Both parties will also conduct comprehensive cooperation in the promotion of high-throughput oncogene testing in China.

The American Society of Clinical Oncology (ASCO) Annual Meeting is recognized globally as one of the most influential and comprehensive clinical oncology conferences. Each year, the conference attracts over 40,000 oncologists and oncology researchers from around the world. The platform enables them to share, debate and collaborate on novel therapies and be at the forefront of cancer research. This year’s theme, “Caring for Every Patient, Learning From Every Patient”, focused on providing all can

Geneseeq is the industrial leader in next-generation sequencing (NGS) technology based genomic profiling for personalized cancer care. Our products and services have served a tremendous number of patients along their journey to conquer cancer. We aim to continuously innovate. Join us in achieving our goal of improving patient outcomes.

Dr. Hua Bao is the Director of Research & Development at Geneseeq. Together with his team, he is responsible for the development of new NGS testing products, computational methods and mathematical modelling in cancer genomics. Dr. Bao began working on NGS data analysis since the invention of this technology. He joined Geneseeq in 2016 as a bioinformatics scientist in the R&D department. In 2018, he was promoted to Head of Bioinformatics of Geneseeq Canada. Dr. Bao has played a key role in our su

President & Chief Executive Officer (Canada)

Dr. Sally Tong is the Director of Operations at Geneseeq Canada. She organizes and oversees the daily operations of the company with thorough knowledge of various company’s processes and company’s products and services. Her goal is to safeguard and augment the efficiency of the company’s operations to facilitate company’s accelerating development and long-term success.

Dr. Xue Wu joined Geneseeq Technology Inc. in 2014 as the Director of Research & Development, bringing more than 10 years of expertise in genomics, oncology and translational medicine to the company. As the leader of Geneseeq’s R&D team, she provided strategic direction and oversight focusing on diagnostic technology and product development, pipeline optimization and translational research in the field of cancer. In 2018, She was promoted to the President & CEO of Geneseeq Canada, and continued

Laboratory accreditation is a benchmark for maintaining the performance competence of clinical tests. Since genetic testing using next-generation sequencing (NGS) technology is more complicated in terms of test performance and the interpretation of results compared to traditional molecular diagnosis methods, the College of American Pathologists (CAP) established the NGS Team in 2011, and published the first NGS Accreditation Requirements in 2012. Such requirements are revised annually as NGS cli

Geneseeq is committed to providing solutions that maximize the treatment benefits for cancer patients, reveal cancer risk, and accelerate precision oncology & clinical research

Contact us today to learn more about our products and services or discuss how we can partner together.

Suite 1802, 393 University Avenue Toronto, Ontario, M5G 1E6 Canada

Geneseeq is a leading Precision Oncology Company offering advanced NGS-Based Precision Oncology services. We provide comprehensive Precision Oncology Solutions for cancer diagnosis, prognosis, treatment guidance, and drug development. Empowering oncologists, researchers, and patients with accurate, actionable genomic insights.

Geneseeq Technology Inc. and its affiliates (collectively, “Geneseeq”, “we”, “our”, “us”) are committed to maintain the privacy and security of your Personal Information that is collected through our interactions with you and through our products, services and events and programs – including our website (collectively, our “Services”). “Personal Information” is information about an identifiable individual. This Privacy Policy provides information about the types of Personal Information we may col

Geneseeq Technology Inc. and its affiliates (collectively, “Geneseeq”, “we”, “our”, “us”) provides the website geneseeq.com, including but not limited to forms and information submitted by you to us on such site (the “Website”) to you subject to these Terms (the “Terms”).